A biomarker study to evaluate the distinct effects of fingolimod on gene expression of T-cell subsets in the blood of patients with multiple sclerosis.
Phase of Trial: Phase IV
Latest Information Update: 24 Dec 2015
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 24 Dec 2015 New trial record